Overview and Response to Previous Review The Robert H. Lurie Comprehensive Cancer Center of Northwestern University (Lurie Cancer Center) is dedicated to the conduct of innovative, translational clinical research. Novel investigator-initiated clinical trials (IITs) are a key element ofthe Lurie Cancer Center clinical research program and are of highest priority. In this competitive granting environment, funding for such studies is often either unavailable or only partially available. While industry sponsors are an important source of funds for such trials, the start-up process with our industry partners can be lengthy. The work of the Operational Efficiency Working Group (OEWG) has made it clear that rapid activation and enrollment to trials is vital. As such, the Lurie Cancer Center is committed to facilitating local, IITs through the CCSG mechanism of Protocol Specific Research Support (PSRS). PSRS funding is competitive in nature and supports protocol coordination and data management for early phase research trials. The goal of such support is to allow for the rapid development and completion of novel, translational hypothesis-driven trials that show promise for advancement to later phase clinical research deserving of independent funding. IITs are those institutional trials that are conceived of and written by Lurie Cancer Center investigators, and fall under the purview ofthe Lurie Cancer Center for ensuring appropriate conduct ofthe trial. Since the last competing application, the Lurie Cancer Center has provided support to 21 trials developed by Lurie Cancer Center members. The funding request for PSRS in this competing application consists of one Study Coordinator and one Data Manager.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Northwestern University at Chicago
United States
Zip Code
Caralt, M; Uzarski, J S; Iacob, S et al. (2015) Optimization and critical evaluation of decellularization strategies to develop renal extracellular matrix scaffolds as biological templates for organ engineering and transplantation. Am J Transplant 15:64-75
Gach, Johannes S; Achenbach, Chad J; Chromikova, Veronika et al. (2014) HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study. PLoS One 9:e85371
Hung, Andy H; Holbrook, Robert J; Rotz, Matthew W et al. (2014) Graphene oxide enhances cellular delivery of hydrophilic small molecules by co-incubation. ACS Nano 8:10168-77
Keller, Jacob Pearson; Homma, Kazuaki; Duan, Chongwen et al. (2014) Functional regulation of the SLC26-family protein prestin by calcium/calmodulin. J Neurosci 34:1325-32
Zhao, Baobing; Keerthivasan, Ganesan; Mei, Yang et al. (2014) Targeted shRNA screening identified critical roles of pleckstrin-2 in erythropoiesis. Haematologica 99:1157-67
Jensen, Samuel A; Calvert, Andrea E; Volpert, Giora et al. (2014) Bcl2L13 is a ceramide synthase inhibitor in glioblastoma. Proc Natl Acad Sci U S A 111:5682-7
Daugherty, Rebecca L; Serebryannyy, Leonid; Yemelyanov, Alex et al. (2014) ?-Catenin is an inhibitor of transcription. Proc Natl Acad Sci U S A 111:5260-5
Anderson, Mark T; Dewenter, Lena; Maier, Berenike et al. (2014) Seminal plasma initiates a Neisseria gonorrhoeae transmission state. MBio 5:e01004-13
Cull, Elizabeth H; Altman, Jessica K (2014) Contemporary treatment of APL. Curr Hematol Malig Rep 9:193-201
Brahmer, J R; Lee, J W; Traynor, A M et al. (2014) Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503). Eur J Cancer 50:302-8

Showing the most recent 10 out of 316 publications